Fig. 1 · Structure
Documents & Downloads
Ravoxertinib hydrochloride
ERK Inhibitor
Ravoxertinib hydrochloride is an orally bioavailable inhibitor that selectively targets ERK kinase activity, demonstrating IC50 values of 6.1 nM for ERK1 and 3.1 nM for ERK2. This compound exhibits significant inhibition of ERK signaling pathways, making it a valuable tool for research in cancer biology and targeted therapies. Its selective action on ERK kinases positions it as an important reagent for investigating therapeutic strategies in ERK-driven malignancies.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 2070009-58-2 |
| Applications | ERK Inhibitor |
| Formula | C21H19Cl2FN6O2 |
| Molecular Weight | 477.32 |
| Synonyms | GDC-0994 hydrochloride |
| SMILES | O=C1C=C(C2=NC(NC3=CC=NN3C)=NC=C2)C=CN1[C@@H](C4=CC=C(Cl)C(F)=C4)CO.Cl[H] |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.